<DOC>
	<DOCNO>NCT01144351</DOCNO>
	<brief_summary>The purpose study determine safety tolerability ELND002 patient relapse form secondary progressive multiple sclerosis ( SPMS ) relapsing-remitting multiple sclerosis ( RRMS ) .</brief_summary>
	<brief_title>A Safety Efficacy Study ELND002 Patients With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Has either clinically definite laboratorysupported definite relapsing form MS least 2 year Patients SPMS RRMS document medical history relapse past year MRIdocumented evidence MS activity past year Has inadequate response intolerability interferon and/or glatiramer acetate Is able willing undergo Gd administration repeat MRI testing Has primary progressive MS ( PPMS ) Any history treatment recombinant humanize monoclonal antibody Has receive treatment immunosuppressant medication experimental agent within 3 month prior Baseline A history opportunistic infection presence active infection within 3 month prior Baseline Any history congestive heart failure currently pacemaker Has know suspect hypersensitivity sulfonamides component investigational drug Has medical history psychiatric condition would impact outcome study participation Has clinically significant abnormality physical , neurological , laboratory , ECG examination list protocol Screening Phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>MS</keyword>
	<keyword>SPMS</keyword>
	<keyword>RRMS</keyword>
	<keyword>Relapsing Forms Secondary Progressive Multiple Sclerosis ( SPMS )</keyword>
	<keyword>Relapsing-Remitting Multiple Sclerosis ( RRMS )</keyword>
</DOC>